What to Do If You Get Diagnosed with an Ovarian Cyst
Ovarian cysts, which are small fluid-filled sacs that develop in or on the ovaries, are very common and are usually harmless.
In fact, 'the process of ovulation—maturing an egg and releasing it—basically makes at least a little cyst, which pops when the egg is released, and then these cysts resolve,' explains Dr. Mary Jane Minkin, an ob-gyn at Yale Medicine. These are often called 'functional cysts,' and they usually go away on their own.
Other types of ovarian cysts include hemorrhagic cysts (which bleed and cause pain), dermoid cysts (which may contain skin cells and sebaceous glands), and endometriomas (which are filled with dark, thick blood and develop as a result of endometriosis). Ovarian cysts also can occur with polycystic ovary syndrome (PCOS), but they don't always.
Here's what to know about ovarian cysts.
How ovarian cysts affect women
Most ovarian cysts are the size of a grape or cherry and don't cause symptoms. But cysts that grow quickly can cause pain in the pelvis near the hipbone and a feeling of persistent pressure. 'This discomfort can be intermittent or constant and may feel sharp or dull,' says Dr. Kelli V. Burroughs, an ob-gyn at UT Health—University of Texas Medical School at Houston.
By contrast, cysts that rupture or burst can cause intense pelvic pain and sometimes slight bleeding, says Minkin. 'The pain will get better as the fluid gets absorbed by the lining of the abdominal cavity.'
Read More: Can You Actually Delay Menopause?
Also, with a complication called ovarian torsion, the ovary can become twisted around the supporting tissue if a cyst gets large, says Dr. Michael B. Baldonieri, an ob-gyn at the Case Western University School of Medicine. 'This can cause unrelenting, severe lower pelvic pain, along with nausea and vomiting.' This is considered a medical emergency because a torsion can cut off the blood supply to the ovary, causing the ovary to die if it's not surgically untwisted.
How most ovarian cysts are treated
What an ovarian cyst looks like on a transvaginal ultrasound and how it's affecting a woman helps determine how it's treated, says Dr. Daniel Ginn, an assistant clinical professor of obstetrics and gynecology at UCLA. If it looks like a collection of fluid in a small pouch or balloon and if the woman has minimal or no symptoms, a doctor may recommend 'watchful waiting'—monitoring symptoms and repeating a pelvic ultrasound every six to eight weeks to see if the cyst has changed in size.
During an ultrasound, a clinician will assess the size and structure of the mass, where it's located, and any other notable features, 'all of which can help differentiate benign from potentially malignant growths,' Burroughs says.
Women with ovarian cysts often worry that they could be a sign of ovarian cancer. While that's possible, it's not common. If a mass on the ovary has solid components as well as fluid, it could be a sign of ovarian cancer. 'An ultrasound usually gives us a good idea if the cyst has some solid components,' says Minkin.
But if the cyst is clearly fluid-filled and hasn't changed over time, the risk of cancer is low, even among older women. A study in a 2024 issue of the American Journal of Obstetrics & Gynecology found that among women ages 50 and older who had stable ovarian cysts detected on ultrasound, the risk of ovarian cancer was 0.27% over a follow-up period of 3.5 years.
On the other hand, 'cysts that get bigger are concerning,' says Ginn. And 'if there's abnormal blood flow through a cyst or fingerlike projections at the periphery of a cyst, that's more concerning.' In these instances, a doctor may order blood tests to measure cancer antigen 125 (CA 125, for short), a protein that's often elevated when someone has ovarian cancer, and other tumor markers.
If a cyst's appearance raises concerns—especially if the woman has elevated CA 125 levels—she will likely be referred to a gynecologic oncologist for specialized evaluation and treatment.
If an ovarian cyst isn't causing symptoms or only mild ones, it may not need to be treated and can simply be monitored over time. 'Two-thirds of ovarian cysts are going to resolve on their own,' Ginn says.
How to feel better
For ovarian cysts that cause pain, medications such as acetaminophen, ibuprofen, or another non-steroidal anti-inflammatory (NSAID) drug can help, Baldonieri says. So can applying a heat or ice pack—whichever feels better to you—to the painful area.
If a cyst is large enough or causing serious discomfort, it can be removed through laparoscopic surgery, which is performed with small incisions through the abdomen, Ginn says. 'Ovarian preservation is always a priority so you can keep your hormones, which are important for heart health, bone health, and cognition.'
For women who frequently get large or painful cysts, 'we try to suppress ovulation, which is why ovarian cysts emerge in the first place,' says Ginn. This is usually done with oral contraceptives (or their hormonal equivalent), which can help prevent new cysts from forming.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Everything you need to know about headaches for Headache Awareness Month
NEW HAVEN, Conn. (WTNH) — June is Headache Awareness Month. In today's health headlines, we discuss what to know about the most common headache types, how to tell them apart, and tips for preventing a tension headache. Dr. Vanessa Cooper, Yale Medicine neurologist specializing in headaches and assistant professor at Yale School of Medicine, joined Good Morning Connecticut at 9 a.m. to discuss. Watch the video above to learn more. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Forbes
7 hours ago
- Forbes
Why Women's Health Research Still Lags Behind
Woman chemist testing for gender differences. The gender gap in healthcare isn't just a question of equity—it's a question of evidence. For too long, women have been excluded from clinical trials, overlooked in preclinical research, and underserved by healthcare systems. The consequences are both deeply personal and widely systemic: Women are more likely to be misdiagnosed, experience adverse drug reactions, and face delays in care. 'It's like death by a thousand paper cuts,' said Alisa Wilson, managing director at Accenture, in a recent interview. 'We're tackling this problem piecemeal, when what's needed is a holistic overhaul across the entire healthcare ecosystem.' New research from Accenture and Springboard Enterprises, 2025 State of Women's Health, sheds light on just how pervasive these gaps are—and what it will take to close them. Bias starts early and compounds over time. Preclinical research—the scientific foundation for nearly all therapies—is still dominated by male models. Animal studies, cell lines, and early-phase drug testing frequently rely on male subjects, based on the outdated assumption that male data is 'universal.' The result? Research hypotheses, safety profiles, and drug mechanisms are skewed from the start. Source: Accenture and Springboard 2025 State of Women's Health That bias continues into clinical trials. Even when women are included, they are often underrepresented or excluded from subgroup analyses. Women made up only 29% of heart attack clinical trial participants, even though heart disease is the number one killer of women globally, according to Accenture's analysis of data from 2020 to 2024. Women also represent just 60% of autoimmune trial participants, even though they make up about 80% of people with autoimmune conditions. 'There's a clear lack of sex-specific data,' said Miranda Ewald, director of programs at Springboard. 'When women are included in research, their outcomes are often not analyzed separately. That makes it impossible to understand how diseases or treatments affect them differently.' Lack of sex-specific dosing, unequal access to optimal treatments and unique challenges to ... More medication contribute to women's poorer health outcomes Even before a clinical trial is an option, women face significant hurdles in getting a diagnosis. On average, it takes up to 7 years to be diagnosed with conditions like polycystic ovarian syndrome (PCOS) or endometriosis. These delays are often dismissed as stress, aging, or psychosomatic symptoms. Despite biological differences, drug dosing rarely accounts for sex. Amani Bright, senior program manager at Springboard, emphasizes the importance of empathy in solving this problem. 'We need decision-makers—funders, policymakers, and healthcare systems—to understand how long and frustrating the patient journey is until they are diagnosed and treated correctly. Women are being left behind because their symptoms don't fit the outdated mold.' That frustration is not limited to patients. Healthcare innovators are also encountering barriers. 'Even with strong scientific validation, women's health startups still face real hurdles—like undefined regulatory pathways and unclear reimbursement models,' said Alice Zheng, partner at Foreground Capital. 'That slows everything down.' Despite these barriers, a new wave of innovators is reimagining how healthcare can better serve women. Companies are working to correct historical research bias by designing more inclusive clinical trials, often in partnership with patient advocacy groups and underrepresented communities. They're also thinking creatively about data collection. 'We're seeing startups use virtual consent tools and culturally sensitive materials to boost trial participation,' said Bright. 'And they're considering real-world factors like language, caregiving responsibilities, and transportation needs.' But to truly accelerate progress, innovators need more support from the healthcare establishment. 'When we worked with a major life sciences client, it took two years just to integrate sex-based thinking into their R&D pipeline,' said Wilson. 'They had never considered sex differences at the discovery stage. That's how deeply ingrained the male-default model is.' Emerging technologies, such as artificial intelligence (AI) and machine learning, offer promise in shortening the research-to-treatment gap. 'We saw how fast COVID vaccines came to market when urgency and collaboration aligned,' said Wilson. 'AI can do the same for women's health if we commit to using high-quality, inclusive data.' However, there is a caveat here as well. AI models trained on biased datasets will only perpetuate the problem. 'To leverage AI effectively, we need to ensure that data is disaggregated by sex, race, and age,' said Wilson. 'Only then can we track adverse events accurately, tailor dosage by gender, and improve safety and efficacy for all patients.' Part of the problem, all interviewees agree, is definitional. When many people hear 'women's health,' they think of reproductive health—fertility, contraception, and menopause. Those areas deserve investment, but they are just one part of a much larger picture. 'The market opportunity is not just the uterus,' said Bright. 'Women's health includes cardiovascular, autoimmune, mental health, and cognitive aging—all areas where women are differently or disproportionately impacted.' Zheng echoed this: 'If we think women's health only means OB-GYN, we're missing the big picture. Breast cancer, for example, is often called a 'solved' disease—but for women with dense breast tissue, early screening is still inadequate.' Fixing the gender gap in medicine requires systemic change. That includes: Most importantly, it requires the healthcare system to see women not as a special case, but as a default patient. The women's health gap is not a niche issue—it's a symptom of centuries of systemic neglect that continues to hinder progress in women's health innovation. When women are misdiagnosed, overlooked, or excluded from research, the entire healthcare system suffers. 'We don't need another pilot program,' said Wilson. 'We need full-scale transformation—led by research, powered by investment, and centered on the real-life experiences of women.' Advancing women's health research and innovation starts with closing the data gap—and ultimately, closing the outcomes gap.
Medscape
10 hours ago
- Medscape
Hyperinsulinemia Linked to Abnormal Uterine Bleeding
Hyperinsulinemia appears to have an early association with common causes of abnormal uterine bleeding (AUB), particularly in women with obesity, a preliminary study in Menopause found. Although preliminary, the study data suggested the opportunity for future research on potential relationships between cardiovascular disease risk factors and gynecologic disease. 'Many studies and organizational bodies have examined and asserted a relationship between polycystic ovarian syndrome (PCOS) and elevated insulin levels,' wrote investigators led by Andrea C. Salcedo, DO, MPH, of the Department of Obstetrics and Gynecology at Loma Linda University in Loma Linda, California. They noted that AUB is the most common reason for benign gynecologic consultation in the United States. Andrea C. Salcedo, DO, MPH 'After over 15 years of clinical practice , I started realizing there were several patterns in women who presented with irregular or heavy periods. Many were self-referred or sent by their primary care providers to see me to evaluate for female hormone problems,' Salcedo told Medscape Medical News . 'The majority were not in perimenopause, but they had similar risk factors for cardiovascular disease, such as obesity, hypertension, and migraine headaches.' Salcedo began to wonder whether healthcare providers are recognizing abnormal periods in reproductive age as a cardiovascular risk and using them to educate women on prevention rather than solely treating them medically or surgically. 'I believe that the theory of the uterus as an 'end organ' that receives inflammation in the same way as the heart and kidneys do in cardiovascular disease helps explain to the patient the reasons for heavy or irregular periods.' The study findings came as no surprise to her: 'They confirmed the patterns I was seeing clinically.' Hyperinsulinemia is associated with smooth blood vessel inflammation in the peripheral circulation. 'What is often under-recognized is that the uterus is made of these same blood vessels.' When the uterus is on the receiving end of inflammation, the blood vessels are damaged and do not function appropriately. The result can be uterine fibroids or heavy periods. The gynecologic expression of this inflammation can vary from person to person, she added. The Study This exploratory cross-sectional analysis of the association between hyperinsulinemia and biomarkers of metabolic syndrome in reproductive-aged women with AUB was designed to motivate future hypothesis-driven research. It was conducted from June 2019 to August 2023 at a single institution's outpatient gynecology clinics. A total of 205 premenopausal women aged 18-54 years were enrolled, including 116 with AUB and 89 control individuals with normal menstrual cycles. Approximately 40% in each group were identified as Hispanic. Participants underwent assessment for fasting insulin and additional markers of metabolic syndrome, including body mass index (BMI), high-density lipoprotein (HDL), low-density lipoprotein (LDL), and waist-to-hip ratio. Among the findings: • Hyperinsulinemia, the main effect of interest, was a significant predictor of AUB, affecting 44.0% of the AUB group vs 33.7% of the control group, with an odds ratio of 3.0 (95% CI, 1.372-6.832; P = .0085). • Hypertension, LDL, HDL, smoking, migraines, and polyps or fibroids were all significantly associated with AUB and identified as confounders. Chronic hypertension was identified in 26% of the AUB group vs 12% of the control group. • Interestingly, including BMI in the model diminished the significance of hyperinsulinemia, suggesting overlapping or mediating pathways, the authors said. • Among metabolic markers, LDL levels were similar between groups, while HDL levels were lower in women with AUB (54.0 vs 60.0 mg/dL). • There was a nonsignificant intergroup difference in triglycerides (82.0 vs 73.5 mg/dL) and total cholesterol levels (169.0 vs 172.5 mg/dL). • Migraines were more prevalent in the AUB group (31.0% vs 11.2%), as were polyps or fibroids (45.7% vs 9.6%). Commenting on the study but not involved in it, Maureen Whelihan, MD, a gynecologist at the Center for Sexual Health and Education and Elite GYN Care of the Palm Beaches in Greenacres, Florida, called the study an interesting one, 'suggesting that before we see the effects of PCOS, a diagnosis of hyperinsulinemia can be made and managed and that hyperinsulinemia has a direct effect on microinflammatory injury to the uterus.' Maureen Whelihan, MD In her practice, women with insulin resistance and PCOS have major infertility issues. 'About 85% are obese and have lipid disorders. While this study indicates we can make a diagnosis earlier by evaluating fasting insulin, the question is, 'then what?'' she said. The ultimate remedy is diet and lifestyle modification. 'The minute patients understand they must eliminate starch and sugar to lower insulin levels and move their body a little, we lose them,' she said. 'They want a quick fix and nothing that requires them to make difficult decisions and drastic modifications. This is the hard part! We can teach them the pathophysiology all day, but they have to commit to a permanent change in the way they approach diet and exercise.' While the study findings are exploratory and preliminary, Salcedo said, they suggest that abnormal periods may have predictive value. 'In many cases, elevated fasting insulin levels, above 10 µU/mL, could be an early sign of cardiovascular and diabetes disease risk.' In this study, elevated insulin levels were associated with AUB, particularly among those with obesity. 'Therefore, when a patient sees her healthcare provider for irregular periods, it could be an excellent opportunity to discuss the known association of menstrual problems with [cardiovascular] risk factors.' Larger, longitudinal studies are needed, however, to confirm the causal mechanisms, Salcedo said.
